Abstract

RODRIGUEZ-SANZ, M. et al. BMD evolution during treatment with aromatase inhibitors and its relation to the CYP11A1 gene: prospective study in the B-ABLE cohort. Rev Osteoporos Metab Miner [online]. 2015, vol.7, n.4, pp.98-105. ISSN 2173-2345.  https://dx.doi.org/10.4321/S1889-836X2015000400004.

Objectives: The aim of this study was to analyze bone mineral density (BMD) changes throughout aromatase inhibitor (AI) treatment in clinical cases and also consider its association with the CYP11A1 gene and the BMD variation after treatment. Material and methods: The B-ABLE cohort is a prospective study of postmenopausal women with breast cancer, in AI treatment. BMD variation was analyzed during AI treatment, as well as the differences those patients who were treated and not treated previously with tamoxifen (TMX). Three polymorphisms (rs4077581, rs11632698 and rs900798) of the CYP11A1 gene were genotyped for their association with BMD variation. Results: TMX-treated patients presented more rapid BMD loss than those who did not undergo prior TMX treatment (60% less in spine and 46% in femur at 2 years and 70% less in the spine and 63% in the femur at 3 years). However, no significant BMD loss was detected after treatment in either group. The 3 CYP11A1 gene polymorphisms were significantly associated with BMD variation in the femur at the end of the treatment. Conclusions: BMD was reduced more rapidly in patients with prior TMX treatment than in those who only received AI, although no significant differences were detected after treatment. The 3 CYP11A1 gene polymorphisms were associated with BMD variation in response to AI treatment.

Keywords : aromatase inhibitors; bone mineral density; CYP11A1; genetic polymorphisms; tamoxifen.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )